Unknown

Dataset Information

0

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).


ABSTRACT: Activating mutations in the receptor tyrosine kinase FLT3 are present in up to approximately 30% of acute myeloid leukemia (AML) patients, implicating FLT3 as a driver of the disease and therefore as a target for therapy. We report the characterization of AC220, a second-generation FLT3 inhibitor, and a comparison of AC220 with the first-generation FLT3 inhibitors CEP-701, MLN-518, PKC-412, sorafenib, and sunitinib. AC220 exhibits low nanomolar potency in biochemical and cellular assays and exceptional kinase selectivity, and in animal models is efficacious at doses as low as 1 mg/kg given orally once daily. The data reveal that the combination of excellent potency, selectivity, and pharmacokinetic properties is unique to AC220, which therefore is the first drug candidate with a profile that matches the characteristics desirable for a clinical FLT3 inhibitor.

SUBMITTER: Zarrinkar PP 

PROVIDER: S-EPMC2756206 | biostudies-literature | 2009 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications


Activating mutations in the receptor tyrosine kinase FLT3 are present in up to approximately 30% of acute myeloid leukemia (AML) patients, implicating FLT3 as a driver of the disease and therefore as a target for therapy. We report the characterization of AC220, a second-generation FLT3 inhibitor, and a comparison of AC220 with the first-generation FLT3 inhibitors CEP-701, MLN-518, PKC-412, sorafenib, and sunitinib. AC220 exhibits low nanomolar potency in biochemical and cellular assays and exce  ...[more]

Similar Datasets

| S-EPMC8417744 | biostudies-literature
| S-EPMC11193555 | biostudies-literature
| S-EPMC9872318 | biostudies-literature
| S-EPMC5882915 | biostudies-literature
| S-EPMC6497874 | biostudies-literature
| S-EPMC5815916 | biostudies-literature
| S-EPMC7873265 | biostudies-literature
| S-EPMC5452050 | biostudies-literature
| S-EPMC8255005 | biostudies-literature
| S-EPMC4855528 | biostudies-literature